What is Oric?
Headquartered in South San Francisco, Oric is a specialized biotechnology company dedicated to the development of novel therapeutics that target the mechanisms of resistance in cancer. By focusing on the molecular basis of therapeutic failure, the company aims to improve patient outcomes across a variety of solid tumors. Its pipeline is characterized by a diverse array of small molecule inhibitors, including programs targeting CD73, which position the firm as a significant player in the competitive oncology landscape. Oric's operational model integrates deep scientific research with strategic clinical execution, ensuring that its drug candidates are positioned to address the most challenging aspects of modern cancer therapy.
How much funding has Oric raised?
Oric has raised a total of $383M across 6 funding rounds:
Series A
$15M
Series B
$53M
Series C
$50M
Series D
$55M
Share Placement
$85M
Stock/Share Issuance
$125M
Series A (2014): $15M with participation from Kravis Investment Partners
Series B (2015): $53M led by OrbiMed, The Column Group, Topspin Partners, Foresite Capital, and EcoR1 Capital
Series C (2018): $50M supported by Topspin Fund, TAIHO VENTURES, OrbiMed, Foresite Capital, Fidelity Management & Research Company, Trinitas Capital Management, Memorial Sloan Kettering Cancer Center, NS Investment, and Kravis Investment Partners
Series D (2019): $55M, investors not publicly disclosed
Share Placement (2023): $85M, investors not publicly disclosed
Stock/Share Issuance (2025): $125M with participation from Venrock, SR One, Viking Global Investors, and Point72
Key Investors in Oric
Venrock
A historic venture capital firm based in Palo Alto that partners with founders to build innovative, high-growth healthcare and technology companies.
SR One
A transatlantic biotechnology venture capital firm that specializes in early and growth-stage life sciences companies developing novel therapeutics.
Viking Global Investors
A global investment firm that utilizes research-intensive fundamental analysis to select private and public equity interests across diverse industries.
What's next for Oric?
With the successful closure of this major strategic investment, Oric is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company is expected to prioritize the advancement of its lead assets while potentially exploring new therapeutic modalities to combat resistance. As the firm continues to scale, the focus will likely shift toward data generation and potential regulatory milestones, supported by a robust syndicate of life sciences investors. This capital deployment will be instrumental in maintaining Oric's competitive edge in the oncology sector, enabling the team to translate complex biological insights into viable, life-saving medicines for patients facing limited treatment options.
See full Oric company page
